Alkermes (NASDAQ:ALKS) Issues FY 2025 Earnings Guidance

Key Points

• Alkermes updated its FY 2025 earnings guidance, projecting EPS between 1.030 and 1.210 and revenue of $1.3 billion to $1.4 billion, both below consensus estimates.
• Recent analyst reports show a mix of ratings, with several firms affirming a "buy" rating and price targets ranging from $40.92 to $45.00.
• Alkermes reported a 12.6% year-over-year decline in revenue for its last quarter, with an EPS of $0.13 that fell short of the consensus estimate of $0.32.

Alkermes (NASDAQ:ALKS - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.030-1.210 for the period, compared to the consensus estimate of 1.760. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Alkermes Stock Performance

Shares of ALKS stock traded up $0.06 on Friday, reaching $26.55. 1,587,001 shares of the company's stock traded hands, compared to its average volume of 2,172,861. Alkermes has a 12-month low of $25.56 and a 12-month high of $36.45. The company has a market capitalization of $4.38 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 1.62 and a beta of 0.44. The business's 50 day moving average price is $29.21 and its two-hundred day moving average price is $30.77.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.42 by $0.10. Alkermes had a return on equity of 24.86% and a net margin of 23.15%. The firm had revenue of $390.66 million for the quarter, compared to the consensus estimate of $343.20 million. During the same quarter in the previous year, the company posted $1.16 earnings per share. The business's quarterly revenue was down 2.1% compared to the same quarter last year. Research analysts predict that Alkermes will post 1.31 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on ALKS. Cantor Fitzgerald upgraded Alkermes to a "strong-buy" rating in a research note on Tuesday, May 13th. Robert W. Baird upped their price target on Alkermes from $38.00 to $41.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Royal Bank Of Canada boosted their price objective on Alkermes from $40.00 to $42.00 and gave the stock a "sector perform" rating in a research report on Wednesday. The Goldman Sachs Group assumed coverage on Alkermes in a research report on Tuesday, July 15th. They set a "buy" rating and a $43.00 price objective for the company. Finally, HC Wainwright reissued a "neutral" rating and set a $46.00 price objective on shares of Alkermes in a research report on Monday, July 21st. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Alkermes presently has an average rating of "Moderate Buy" and a consensus target price of $41.08.

Insider Buying and Selling at Alkermes

In other news, SVP Christian Todd Nichols sold 3,334 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the sale, the senior vice president directly owned 86,208 shares in the company, valued at approximately $2,680,206.72. This represents a 3.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.40% of the company's stock.

Institutional Investors Weigh In On Alkermes

Large investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Alkermes by 4.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company's stock valued at $15,927,000 after purchasing an additional 20,091 shares during the period. Royal Bank of Canada grew its position in Alkermes by 117.2% during the 1st quarter. Royal Bank of Canada now owns 275,526 shares of the company's stock worth $9,098,000 after acquiring an additional 148,696 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new stake in Alkermes during the 1st quarter worth approximately $213,000. 95.21% of the stock is currently owned by institutional investors.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.